Urinary tract infections (UTIs) are among the most common bacterial infections worldwide, affecting millions of patients every year. They are a major cause of morbidity, recurrence, and healthcare costs, particularly in women, elderly individuals, and hospitalized patients with catheter-associated UTIs. The growing incidence of multidrug-resistant Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecium poses a serious threat, making the development of new therapeutic approaches an urgent priority.

Skin and soft tissue infections (SSTIs) are among the most common infectious diseases, ranging from superficial infections to severe necrotizing fasciitis. They represent a significant clinical burden, particularly in immunocompromised patients and those with chronic wounds. The global rise of antimicrobial resistance, especially among Staphylococcus aureus and Pseudomonas aeruginosa, underscores the urgent need for new antibiotics, antifungals, and topical formulations.

Pulmonary infections remain a major global health challenge. They are responsible for significant morbidity and mortality and represent one of the leading causes of hospitalization worldwide. The rise of antimicrobial resistance, the emergence of new respiratory pathogens, and the limited number of effective treatments highlight the urgent need for innovative therapies.